OasisLMS

Tumor sequencing is complex, and point-of-care clinicians bear the significant burden of interpreting the large number of somatic and germline variants that emerge from clinical tumor genomic profiling. Explore the evolving landscape of tumor sequencing in clinical oncology and how clinical decision support tools like OncoKB—the first and only somatic human variant database recognized by the FDA—can provide evidence-based guidance for the clinical team.

This live-streaming webinar addresses the challenges of clinical variant interpretation and highlights how the adoption of clinical decision support tools is streamlining precision oncology workflows as well as elucidating complex variants and the hierarchy of data organization.

Learning objectives

• Understand the adoption of precision oncology in both academic cancer centers and community practices
• Understand where knowledge bases such as OncoKB sit within the precision oncology/molecular pathology workflow
• Identify the complexity behind aggregating and standardizing variant annotations from distributed sources
• Outline the hierarchy for data organization to link genes, genetic alterations, indications, and levels of evidence

The Cancer Diagnostics: Transforming Complex to Clear initiative is made possible by support from AstraZeneca, Amgen, BMS, Exact Sciences, Merck and Lilly Oncology

Debyani Chakravarty, PhD

Lead Scientist, ONCOKB, Kravis Center for Molecular Oncology; Assistant Attending Geneticist, Molecular Diagnostics Service Department of Pathology and Laboratory Medicine,

Memorial Sloan Kettering Cancer Center